| Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples M Russano, A Napolitano, G Ribelli, M Iuliani, S Simonetti, F Citarella, ... Journal of Experimental & Clinical Cancer Research 39, 1-13, 2020 | 215 | 2020 |
| Microenvironment drug resistance in multiple myeloma: emerging new players L Di Marzo, V Desantis, AG Solimando, S Ruggieri, T Annese, B Nico, ... Oncotarget 7 (37), 60698, 2016 | 165 | 2016 |
| COVID-19 and the endocrine system: a comprehensive review on the theme G Lisco, A De Tullio, A Stragapede, AG Solimando, F Albanese, ... Journal of clinical medicine 10 (13), 2920, 2021 | 91 | 2021 |
| Bone marrow fibroblasts overexpress miR‐27b and miR‐214 in step with multiple myeloma progression, dependent on tumour cell‐derived exosomes MA Frassanito, V Desantis, L Di Marzo, I Craparotta, L Beltrame, ... The Journal of pathology 247 (2), 241-253, 2019 | 89 | 2019 |
| Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma I Saltarella, V Desantis, A Melaccio, AG Solimando, A Lamanuzzi, R Ria, ... Cells 9 (1), 167, 2020 | 82 | 2020 |
| CAFs and TGF-β signaling activation by mast cells contribute to resistance to gemcitabine/nabpaclitaxel in pancreatic cancer L Porcelli, RM Iacobazzi, R Di Fonte, S Serratì, A Intini, AG Solimando, ... Cancers 11 (3), 330, 2019 | 81 | 2019 |
| Gene expression comparison between the lymph node-positive and-negative reveals a peculiar immune microenvironment signature and a theranostic role for WNT targeting in … A Argentiero, S De Summa, R Di Fonte, RM Iacobazzi, L Porcelli, ... Cancers 11 (7), 942, 2019 | 79 | 2019 |
| A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target A Ferrucci, M Moschetta, MA Frassanito, S Berardi, I Catacchio, R Ria, ... Clinical cancer research 20 (22), 5796-5807, 2014 | 75 | 2014 |
| Cancer-associated angiogenesis: the endothelial cell as a checkpoint for immunological patrolling AG Solimando, SD Summa, A Vacca, D Ribatti Cancers 12 (11), 3380, 2020 | 74 | 2020 |
| The evolving role of immune checkpoint inhibitors in hepatocellular carcinoma treatment P Leone, AG Solimando, R Fasano, A Argentiero, E Malerba, ... Vaccines 9 (5), 532, 2021 | 73 | 2021 |
| Predictive and prognostic factors in HCC patients treated with sorafenib O Brunetti, A Gnoni, A Licchetta, V Longo, A Calabrese, A Argentiero, ... Medicina 55 (10), 707, 2019 | 72 | 2019 |
| Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial A Vacca, A Melaccio, A Sportelli, AG Solimando, F Dammacco, R Ria Clinical immunology 191, 110-115, 2018 | 72 | 2018 |
| JAM-A as a prognostic factor and new therapeutic target in multiple myeloma AG Solimando, A Brandl, K Mattenheimer, C Graf, M Ritz, A Ruckdeschel, ... Leukemia 32 (3), 736-743, 2018 | 71 | 2018 |
| The anti-VEGF (R) drug discovery legacy: improving attrition rates by breaking the vicious cycle of angiogenesis in cancer D Ribatti, AG Solimando, F Pezzella Cancers 13 (14), 3433, 2021 | 70 | 2021 |
| Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma M Moschetta, A Basile, A Ferrucci, MA Frassanito, L Rao, R Ria, ... Clinical cancer research 19 (16), 4371-4382, 2013 | 70 | 2013 |
| Insights into the regulation of tumor angiogenesis by micro-RNAs P Leone, A Buonavoglia, R Fasano, AG Solimando, V De Re, S Cicco, ... Journal of clinical medicine 8 (12), 2030, 2019 | 67 | 2019 |
| Cytotoxic T-lymphocyte antigen-4 in colorectal cancer: another therapeutic side of capecitabine A Derakhshani, S Hashemzadeh, Z Asadzadeh, MA Shadbad, ... Cancers 13 (10), 2414, 2021 | 66 | 2021 |
| Actors on the scene: immune cells in the myeloma niche P Leone, AG Solimando, E Malerba, R Fasano, A Buonavoglia, ... Frontiers in oncology 10, 599098, 2020 | 66 | 2020 |
| Role of BRAF in hepatocellular carcinoma: a rationale for future targeted cancer therapies A Gnoni, A Licchetta, R Memeo, A Argentiero, AG Solimando, V Longo, ... Medicina 55 (12), 754, 2019 | 64 | 2019 |
| Pancreatic cancer signaling pathways, genetic alterations, and tumor microenvironment: The barriers affecting the method of treatment D Javadrashid, A Baghbanzadeh, A Derakhshani, P Leone, N Silvestris, ... Biomedicines 9 (4), 373, 2021 | 62 | 2021 |
Angelo VACCAUniversità degli Studi di BariBestätigte E-Mail-Adresse bei uniba.it
